Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

This is more of an awareness spend than a fundamental inflection. In ADHD, the real economic lever is not top-of-funnel awareness but conversion into paid, persistent scripts; that is governed by physician inertia, prior auth, and tolerability versus cheap generics. So the near-term upside to SUPN is mostly sentiment and possibly a modest lift in new-patient starts, while the longer-term value creation depends on whether the campaign improves refill persistence, which is where non-stimulants can quietly compound.

The first-order winner is SUPN, but the second-order beneficiary could be the broader ADHD diagnosis ecosystem: telehealth evaluators, pediatric practices, and pharmacy channels may see more screening activity even if Qelbree share barely moves. The losers are generic stimulant and atomoxetine franchises only if the campaign nudges patients toward a non-stimulant class; otherwise they absorb the volume with little disruption. Because this is a compensated ambassador program, the market should discount it heavily until verified by prescription data.

Catalyst path is short-term sentiment, then 1-3 month script checks, then 6-18 month share-change evidence. The contrarian view is that this may be over-read as a brand event when it is really a marketing click-through exercise in a category where access and reimbursement dominate. What would falsify the bearish skepticism is a sustained step-up in weekly TRx and better persistence in the next two quarterly prints; absent that, any pop should fade.